Wave Life Sciences Dirección

Dirección controles de criterios 2/4

El CEO de Wave Life Sciences' es Paul B. Bolno , nombrado en Dec 2013, tiene una permanencia de 10.33 años. compensación anual total es $2.67M, compuesta por 23.2% salario y 76.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.33% de las acciones de la empresa, por valor de €1.90M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 7.4 años, respectivamente.

Información clave

Paul B. Bolno

Chief Executive Officer (CEO)

US$3.9m

Compensación total

Porcentaje del salario del CEO	16.4%
Permanencia del CEO	10.4yrs
Participación del CEO	0.3%
Permanencia media de la dirección	3.7yrs
Promedio de permanencia en la Junta Directiva	7.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul B. Bolno en comparación con los beneficios de Wave Life Sciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$62m
Dec 31 2023	US$4m	US$636k	-US$58m
Sep 30 2023	n/a	n/a	-US$85m
Jun 30 2023	n/a	n/a	-US$131m
Mar 31 2023	n/a	n/a	-US$151m
Dec 31 2022	US$3m	US$618k	-US$162m
Sep 30 2022	n/a	n/a	-US$153m
Jun 30 2022	n/a	n/a	-US$120m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$4m	US$597k	-US$122m
Sep 30 2021	n/a	n/a	-US$116m
Jun 30 2021	n/a	n/a	-US$143m
Mar 31 2021	n/a	n/a	-US$145m
Dec 31 2020	US$1m	US$579k	-US$150m
Sep 30 2020	n/a	n/a	-US$178m
Jun 30 2020	n/a	n/a	-US$196m
Mar 31 2020	n/a	n/a	-US$197m
Dec 31 2019	US$4m	US$579k	-US$194m
Sep 30 2019	n/a	n/a	-US$175m
Jun 30 2019	n/a	n/a	-US$162m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$6m	US$541k	-US$147m
Sep 30 2018	n/a	n/a	-US$140m
Jun 30 2018	n/a	n/a	-US$127m
Mar 31 2018	n/a	n/a	-US$116m
Dec 31 2017	US$3m	US$515k	-US$102m

Compensación vs. Mercado: La compensación total de Paul B.($USD2.67M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.29M).

Compensación vs. Ingresos: La compensación de Paul B. ha aumentado mientras la empresa no es rentable.

CEO

Paul B. Bolno (49 yo)

10.4yrs

Permanencia

US$3,874,300

Compensación

Dr. Paul B. Bolno, M.D., MBA served as an Independent Director at SQZ Biotechnologies Company since June 2020 until March 2024. Since May 2020 he has served as Chairman of the Scientific Advisory Group for...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul B. Bolno	President	10.4yrs	US$3.87m	0.33% $ 2.1m
Kyle B. Moran	CFO & Principal Accounting Officer	3.4yrs	US$1.70m	0.028% $ 177.0k
Chandra Vargeese	Chief Technology Officer	4yrs	US$1.78m	0.079% $ 502.7k
Kate Rausch	Head of Investor Relations	5.1yrs	sin datos	sin datos
Linda Rockett	Senior VP & General Counsel	8yrs	sin datos	sin datos
Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	7.3yrs	US$1.68m	0.065% $ 416.0k
Daryn Lewis	Senior VP & Head of Human Resources	1.3yrs	sin datos	sin datos
Sridhar Vaddeboina	Senior Vice President of Chemistry	2.5yrs	sin datos	sin datos
Anne-Marie Li-Kwai-Cheung	Chief Development Officer	1.6yrs	sin datos	sin datos
Hsiu-Chiung Yang	Senior Vice President of Translational Medicine	1.3yrs	sin datos	sin datos

3.7yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1U5 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul B. Bolno	President	10.1yrs	US$3.87m	0.33% $ 2.1m
Gregory L. Verdine	Director	10.8yrs	US$170.74k	0.025% $ 156.5k
Mark H. Corrigan	Independent Director	4.7yrs	US$194.74k	0.059% $ 376.7k
Christian O. Henry	Independent Chairperson	7.5yrs	US$222.24k	0.072% $ 457.9k
Adrian G. Rawcliffe	Independent Director	7.3yrs	US$188.74k	0.072% $ 457.9k
Peter Kolchinsky	Independent Director	9.3yrs	US$170.74k	sin datos
Ken Takanashi	Independent Director	11.8yrs	US$170.74k	0% $ 0
Heidi L. Wagner	Independent Director	4.7yrs	US$185.74k	0.059% $ 376.7k
Aik Na Tan	Independent Director	3.8yrs	US$172.24k	0.047% $ 297.2k

7.5yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 1U5 se considera experimentada (7.4 años de antigüedad promedio).

Wave Life Sciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer

President recently sold €111k worth of stock

Insufficient new directors

Insufficient new directors

Insufficient new directors

Wave Life Sciences Ltd. Announces Management Changes

Recent updates

New major risk - Revenue and earnings growth

Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Wave Life Sciences Ltd. to Report Q1, 2024 Results on May 09, 2024

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.05 loss in FY 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Share price stability

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.41 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q3, 2023 Results on Nov 09, 2023

Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for Wve-006

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.62 loss in 2Q 2022)

Wave Life Sciences Ltd. to Report Q2, 2023 Results on Aug 03, 2023

Wave Life Sciences Announces Topline Results from Phase 1B/2A Focus-C9 Study of WVE-004 for C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

President recently sold €111k worth of stock

Wave Life Sciences Provides Positive Update on Proof-Of-Concept Study for Wve-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Insufficient new directors

Insufficient new directors

Insufficient new directors

Wave Life Sciences Ltd. Announces Management Changes

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Wave Life Sciences Ltd., Annual General Meeting, Aug 09, 2022

Wave Life Sciences Ltd.(NasdaqGM:WVE) dropped from Russell 2000 Dynamic Index

Wave Life Sciences Ltd. Announces First Clinical Data from Ongoing Focus-C9 Trial of Wve-004 for C9-Als and C9-Ftd

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

Wave Life Sciences Ltd. Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

Wave Life Sciences Ltd. Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

President recently sold €68k worth of stock

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.86 loss in 3Q 2020)

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease

First half 2021 earnings released: US$1.65 loss per share (vs US$2.53 loss in 1H 2020)

Wave Life Sciences Ltd. Announces Proof-of-Concept Preclinical Data for Adar Editing Program in Alpha-1 Antitrypsin Deficiency

Full year 2020 earnings released: US$3.82 loss per share (vs US$5.72 loss in FY 2019)

Revenue misses expectations

New 90-day high: €8.35

Wave Life Sciences Ltd. Announces Key Upcoming Milestones for 2021 and Continued Advancement of Proprietary Discovery and Drug Development Platform

Wave Life Sciences Ltd. Announces Resignation of Amy Pott from the Board and the Compensation Committee

New 90-day high: €7.70

Wave Life Sciences Ltd. Announces Management Changes

Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

Revenue misses expectations

Third quarter 2020 earnings released: US$0.86 loss per share

New 90-day low: €6.50

New 90-day low: €6.95

New 90-day high - €11.20

New 90-day low - €7.20

First half earnings released

Wave Life Sciences Ltd.(NasdaqGM:WVE) dropped from S&P Pharmaceuticals Select Industry Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad